Biomarkers for Graft-Versus-Host Disease in Hematopoietic Stem Cell Transplant Patients
Keywords:
Biomarkers, MicroRNAs, Graft Versus Host DiseaseAbstract
Introduction: One of the therapeutic strategies for hematological malignancies is hematopoietic stem cell transplantation (HSCT). However, a common and severe post-transplantation complication is graft-versus-host disease (GVHD), primarily mediated by the donor’s immunocompetent cells, particularly T lymphocytes. Objectives: This study aims to explore potential biomarkers for the prognosis and diagnosis of GVHD following HSCT. Methods: This integrative review was conducted using the PubMed and Google Scholar databases. The research question was structured and refined using the PICO (Population, Intervention, Comparison, and Outcome) method, resulting in the guiding question: “Can biomarkers help in the diagnosis, prognosis, and treatment of GVHD?” The descriptors used were: “graft versus host disease,” “hematopoietic stem cell transplant,” and “microRNAs,” combined with the Boolean operator “AND.” These searches resulted in 1,942 articles, from which 33 were selected based on the English language and relevance to the main objectives of the study, after reviewing their titles and abstracts. Results: Among the biomarkers examined, microRNAs emerge as the most promising due to their stability and ease of extraction from body fluids. While some progress has been made in identifying such markers in recent years, further research is necessary to enhance understanding and ensure their practical application in clinical settings. Conclusion: The importance of finding biomarkers, considered more enlightening and less susceptible to bias compared to traditional diagnostic methods that can predict the risk of GVHD, is demonstrated. Although there are strategies to reduce the risk of developing this complication, such as T lymphocyte depletion, patients undergoing these therapies have a high risk of relapse since the effect called “graft-versus-leukemia” is compromised. Although the search for such markers has achieved some success in recent years, further studies are needed to provide additional clarification and ensure applicability in daily clinical practice. An ideal biomarker should be easily measurable, highly sensitive, and specific, enabling early detection using readily available samples.
Downloads
References
1. Cha’ng YJ, Zhao XY, Huang XJ. Strategies for enhancing and preserving anti-leukemia effects without aggravating graftversus- host disease. Front Immunol, 2018; 9. https://doi.org/10.3389/fimmu.2018.03041
2. Khaddour K, Hana CK, Mewawalla P. Hematopoietic stem cell transplantation. 2021 [cited 2023 Oct 25] Treasure Island (FL): StatPearls Publishing. Available from: https://pubmed.ncbi.nlm.nih.gov/30725636/
3. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol, 2007; 7(5): 340-52. https://doi.org/10.1038/nri2000
4. Ramzi M, Shokrgozar N. MicroRNAs: regulatory biomarkers in acute myeloid leukemia and graft versus host disease. Clin Lab, 2022; 68. https://doi.org/10.7754/clin.lab.2021.210621
5. Balassa K, Danby R, Rocha V. Hematopoietic stem cell transplants: principles and indications. Br J Hosp Med, 2019; 80(1): 33-9. https://doi.org/10.12968/hmed.2019.80.1.33
6. Chiad Z, Chojecki A. Graft versus leukemia in 2023. Best Pract Res Clin Haematol, 2023; 36(3): 101476-6. https://doi.org/10.1016/j.beha.2023.101476
7. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission. JAMA, 2009; 301(22): 2349. https://doi.org/10.1001/jama.2009.813
8. Fuchs EJ. Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology Am Soc Hematol Educ Program, 2012; 2012(1): 230-6. https://doi.org/10.1182/asheducation.V2012.1.230.3798312
9. Apperley J, Niederwieser D, Huang X, Nagler A, Fuchs E, Szer J, et al. Haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant, 2016; 22(1): 23-6. https://doi.org/10.1016/j.bbmt.2015.11.001
10. Warren EH, Deeg HJ. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. Tissue Antigens, 2013; 81(4): 183-93. https://doi.org/10.1111/tan.12090
11. Moreno DF, Cid J. Graft-versus-host disease. Med Clin, 2019; 152(1): 22-8. https://doi.org/10.1016/j.medcle.2018.11.008
12. Spyrou N, Levine JE, Ferrara JLM. Acute GVHD: new approaches to clinical trial monitoring. Best Pract Res Clin Haematol, 2022; 35(4): 101400. https://doi.org/10.1016/j.beha.2022.101400
13. Zeiser R, Teshima T. Nonclassical manifestations of acute GVHD. Blood, 2021; 138(22): 2165-72. https://doi.org/10.1182/blood.2021012431
14. Hamilton BK. Updates in chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program, 2021; 2021(1): 648-54. https://doi.org/10.1182/hematology.2021000301
15. Martin PJ, Levine DM, Storer BE, Warren EH, Zheng X, Nelson SC, et al. Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. Blood, 2017; 129(6): 791-8. https://doi.org/10.1182/blood-2016-09-737700
16. Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. Orphanet J Rare Dis, 2007; 2(1). https://doi.org/10.1186/1750-1172-2-35.
17. Sarhadi VK, Armengol G. Molecular biomarkers in cancer. Biomolecules, 2022; 12(8): 1021. https://doi.org/10.3390/biom12081021
18. Ali AM, DiPersio JF, Schroeder MA. The role of biomarkers in the diagnosis and risk stratification of acute graft-versus-host disease: a systematic review. Biol Blood Marrow Transplant, 2016; 22(9): 1552-64. https://doi.org/10.1016/j.bbmt.2016.04.022
19. Srinagesh HK, Levine JE, Ferrara JLM. Biomarkers in acute graft-versus-host disease: new insights. Ther Adv Hematol, 2019; 10. https://doi.org/10.1177/2040620719891358
20. Sauer S, Johannes H, Jacek H, Neumann F, Aleksandar R, Ho AD, et al. A prospective study on serum c ytokeratin (CK)-18 and CK18 fragments as biomarkers of acute hepato-intestinal GVHD. Leukemia, 2018; 32(12): 2685-92. https://doi.org/10.1038/s41375-018-0183-0
21. Li A, Bhatraju PK, Chen J, Chung DW, Hilton T, Houck K, et al. Prognostic biomarkers for thrombotic microangiopathy after acute graft-versus-host disease: a nested case-control study. Transplant Cell Ther, 2020; 27(4): 308.e1-8. https://doi.org/10.1016/j.jtct.2020.12.010
22. Giaccone L, Faraci DG, Butera S, Lia G, Vito CD, Gabrielli G, et al. Biomarkers for acute and chronic graft versus host disease: state of the art. Expert Rev Hematol, 2020; 14(1): 79-96. https://doi.org/10.1080/17474086.2021.1860001
23. Lia G, Brunello L, Bruno S, Carpanetto A, Omedè P, Festuccia M, et al. Extracellular vesicles as potential biomarkers of acute graft-vs-host disease. Leukemia, 2017; 32(3): 765-73. https://doi.org/10.1038/leu.2017.277
24. Wolff D, Greinix H, Lee SJ, Gooley T, Paczesny S, Pavletic S, et al. Biomarkers in chronic graft-versus-host disease: quo vadis? Bone Marrow Transplantation, 2018; 53(7): 832-7. https://doi.org/10.1038/s41409-018-0092-x
25. Łacina P, Crossland RE, Wielińska J, Czyż A, Szeremet A, Ussowicz M, et al. Differential expression of miRNAs from extracellular vesicles in chronic graft-versus-host disease: a preliminary study. Adv Clin Exp Med, 2022; 32(5): 539-44. https://doi.org/10.17219/acem/155373
26. Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol, 2010; 223(2): 102-15. https://doi.org/10.1002/path.2806
27. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol-Mech, 2014; 9(1): 287-314. https://doi.org/10.1146/annurev-pathol-012513-104715
28. Reikvam H, Vo AK, Johansen S, Hemsing AL, Solheim MH, Knut AM, et al. MicroRNA serum profiles and chronic graftversus-host disease. Blood Adv, 2022; 6(18): 5295-306. https://doi.org/10.1182/bloodadvances.2021005930
29. Montoya RT, Oriana LG, Nuria GB, Cifuentes-Riquelme R, Sola M, Heras I, et al. Identification of circulating microRNA signatures as potential noninvasive biomarkers for prediction to response to extracorporeal photoapheresis in patients with graft versus host disease. Blood, 2019; 134: 4466-6. https://doi.org/10.1182/blood-2019-121655
30. Giesen N, Schwarzbich MA, Dischinger K, Becker N, Hummel M, Benner A, et al. CXCL9 predicts severity at the onset of chronic graft-versus-host disease. Transplantation, 2020; 104(11): 2354-9. https://doi.org/10.1097/TP.0000000000003108
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Isabella Brandão Russo da Costa, Amanda Camila Val de Melo, Fernando Callera, Mariella Vieira Pereira Leão
This work is licensed under a Creative Commons Attribution 4.0 International License.
